Grey Fox Wealth Advisors LLC Acquires Shares of 2,285 Gilead Sciences, Inc. (NASDAQ:GILD)

Grey Fox Wealth Advisors LLC bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 2,285 shares of the biopharmaceutical company’s stock, valued at approximately $211,000.

Other large investors have also made changes to their positions in the company. Avior Wealth Management LLC grew its holdings in Gilead Sciences by 1.2% in the 3rd quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company’s stock valued at $782,000 after buying an additional 108 shares in the last quarter. Southland Equity Partners LLC grew its holdings in shares of Gilead Sciences by 3.6% in the fourth quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company’s stock valued at $289,000 after purchasing an additional 110 shares during the period. Berkshire Bank increased its position in Gilead Sciences by 3.4% during the fourth quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company’s stock worth $314,000 after purchasing an additional 111 shares during the last quarter. CFO4Life Group LLC boosted its holdings in Gilead Sciences by 2.7% in the 4th quarter. CFO4Life Group LLC now owns 4,265 shares of the biopharmaceutical company’s stock valued at $394,000 after purchasing an additional 112 shares during the last quarter. Finally, GHP Investment Advisors Inc. grew its stake in shares of Gilead Sciences by 1.1% in the 4th quarter. GHP Investment Advisors Inc. now owns 11,354 shares of the biopharmaceutical company’s stock valued at $1,049,000 after buying an additional 122 shares during the period. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 17,929 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $118.17, for a total value of $2,118,669.93. Following the completion of the sale, the chief financial officer now owns 169,061 shares in the company, valued at approximately $19,977,938.37. The trade was a 9.59 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last three months, insiders sold 302,785 shares of company stock valued at $30,503,250. Insiders own 0.29% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. DZ Bank upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price objective on the stock in a report on Thursday, February 13th. Oppenheimer increased their price target on Gilead Sciences from $115.00 to $132.00 and gave the stock an “outperform” rating in a report on Tuesday, March 4th. Royal Bank of Canada boosted their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a report on Wednesday, February 12th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a research note on Wednesday, January 29th. Eleven investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $104.52.

Gilead Sciences Trading Down 2.5 %

GILD opened at $107.51 on Thursday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96. The company has a market cap of $133.89 billion, a P/E ratio of 290.57, a PEG ratio of 0.71 and a beta of 0.21. The business’s 50-day simple moving average is $103.00 and its 200-day simple moving average is $93.47.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be given a dividend of $0.79 per share. The ex-dividend date is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.94%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s payout ratio is 854.05%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.